Venetoclax to Augment Epigenetic Modification and Chemotherapy

The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients.

Trial Details

NCT ID
NCT05317403
Phase
PHASE1
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax
  • Azacitadine
  • Vorinostat
  • Cytarabine
  • Fludarabine
  • Filgrastim
Locations (sample)
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Patients with AML must have measurable disease (≥M1 marrow) in the bone marrow.
  • 1st or greater relapse, OR
  • Failed to go into remission after 1st or greater relapse, OR
  • Failed to go into remission from original diagnosis after 2 or more induction attempts

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →